May 11, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting, held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a […]
• Read MoreMay 9, 2022
The Annual General Meeting of LungLife AI,Inc. the “Company”) to be held at 2:00 p.m. BST on 11 May 2022 at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, United Kingdom (including any adjournment or postponement thereof, the “AGM”). Stockholders will be able to listen live to the AGM by accessing the below Microsoft […]
• Read MoreApril 8, 2022
8 April 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read MoreMarch 28, 2022
28 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary results LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its maiden audited preliminary results for the year ended 31 December 2021, following admission to trading on AIM on 8 July 2021. Summary and Highlights for the year: Revenues […]
• Read MoreMarch 17, 2022
17 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Veterans Affairs (VA) sites added to validation study with first Veteran enroled Key lung cancer specialist, Dr Drew Moghanaki, appointed to Scientific Advisory Board LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its pivotal clinical study to evaluate the […]
• Read MoreMarch 8, 2022
8 March 2022 LungLife AI, Inc. (the "Company" or "LungLife") Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2021 on Monday 28 March 2022. Investor presentation Paul Pagano, Chief Executive Officer, and David […]
• Read MoreFebruary 2, 2022
2 February 2022 LungLife AI, Inc. (the “Company” or “LungLife”) First patient enrolment for LungLB® validation study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has enrolled its first patient in its pivotal clinical study to evaluate the LungLB® test in subjects presenting with indeterminate lung nodules. The […]
• Read MoreJanuary 4, 2022
4 January 2022 LungLife AI, Inc. (the “Company” or “LungLife”) CPT® Code granted by American Medical Association Successful grant marks first step facilitating commercial reimbursement LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT® Proprietary Laboratory Analyses (PLA) code for its LungLB® […]
• Read MoreNovember 22, 2021
19 November 2021 LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI Clinical Laboratory achieves CAP accreditation Independent inspection confirms highest standard of care for laboratory patients LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California […]
• Read MoreNovember 22, 2021
10 November 2021 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Application LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the “Block Admission”) has been made to the London Stock Exchange for up to 1,356,139 common shares of US […]
• Read More
LungLife AI licensure/accreditation information posted here.